Finding New Targets on the Surface of Misfolded Proteins

Finding New Targets on the Surface of Misfolded One of the biggest hurdles in drug development is targeting proteins found in both healthy and diseased cells without triggering toxic side effects. In cancer, this challenge often translates into narrow therapeutic windows, collateral damage to normal tissues, and forced dose reductions that limit efficacy. The result is a crowded field where many companies chase the same well-known targets, leaving vast patient populations without effective options. Immuto Scientific is taking a different approach. The company is redefining how targets are identified—focusing not on genetic sequence, but on disease-specific protein conformations. By studying the structural shapes that proteins take in malignant cells, Immuto aims to distinguish cancerous from healthy tissue, broaden therapeutic windows, and unlock new or previously undruggable targets across oncology and beyond. We spoke with Faraz Choudhury, co-founder and CEO of Immuto Scientific, about the company’s AI-enabled structural surfaceomics platform, how it allows drugs to selectively home in on diseased cells while sparing normal ones, and Immuto’s plans to extend its science into immunology and inflammation. Proteins